Seres Therapeutics Inc (MCRB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $14.27M
Last updated: Nov 17, 2026 at 11:05 AM ET
Seres Therapeutics Inc (MCRB) Stock Forecast
Analysts expect Seres Therapeutics (MCRB) to earn -$4.81 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.00M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.95.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 78.9%.
- Fiscal year ending Dec 31, 2026
- -$4.81
- EPS consensus, revenue $2.00M
- Fiscal year ending Dec 31, 2027
- -$1.95
- EPS consensus, revenue $422000
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.81 | -$4.81 to -$4.81 | 1 | $2.00M | $2.00M to $2.00M | 1 |
| Dec 31, 2027 | -$1.95 | -$2.12 to -$1.77 | 2 | $422000 | N/A | 2 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.66 | -$1.53 to $0.28 | 4 | $6.53M | $303800 to $13.13M | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.52.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.81 | -$3.52 | -$3.52 | -$3.52 | -$3.52 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.95 | -$4.95 | -$4.95 | -$4.95 | -$4.95 | N/A |
Frequently Asked Questions About MCRB
What is the MCRB stock forecast?
Consensus analyst estimates put Seres Therapeutics's EPS at -$4.81 for the fiscal year ending Dec 31, 2026, on revenue of $2.00M.
What EPS do analysts expect from MCRB next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.81, with estimates from -$4.81 to -$4.81 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.95, with estimates from -$2.12 to -$1.77 from 2 analysts.
What revenue do analysts expect from Seres Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.00M, with estimates from $2.00M to $2.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $422000.
How many analysts cover MCRB?
1 analyst estimates EPS for Seres Therapeutics for the fiscal year ending Dec 31, 2026.
MCRB pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors